WCN25-3787 EFFECT OF CHOLECALCIFEROL SUPPLEMENTATION ON SARCOPENIA IN SARCOPENIC END STAGE RENAL DISEASE PATIENTS

WCN25-3787 EFFECT OF CHOLECALCIFEROL SUPPLEMENTATION ON SARCOPENIA IN SARCOPENIC END STAGE RENAL DISEASE PATIENTS

Saved in:

Bibliographic Details
Main Authors:	Disha Arora, Dr. Himansu Sekhar Mahapatra, Lalit pursnani, Muthu Kumar Balakrishnan, Renju Binoy
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924026159
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-403 THIRTY DAYS OUTCOMES OF SUSTAINED LOW EFFICIENCY DIALYSIS IN CRITICALLY ILL PATIENTS OF AKI AND ACUTE ON CKD
by: MD.MAHBOOB ALAM, et al.
Published: (2025-02-01)

WCN25-4437 SUCCESSFUL LONG-TERM MANAGEMENT OF LUPUS NEPHRITIS WITH DISSEMINATED RENAL AND GASTROINTESTINAL CRYPTOCOCCOSIS: A CASE REPORT
by: vipin dev, et al.
Published: (2025-02-01)

WCN25-4481 CRIMSON CLUES: GROSS HEMATURIA AS A MANIFESTATION OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA- A UNIQUE CASE REPORT
by: Varuna Yadav, et al.
Published: (2025-02-01)

WCN25-3503 CHALLENGES IN EXTERNAL JUGULAR VEIN TUNNELED CATHETER PLACEMENT: INSIGHTS FROM A TERTIARY CARE CENTER EXPERIENCE
by: beauty suman, et al.
Published: (2025-02-01)

WCN25-428 COMPARISON OF SHORT TERM MORTALITY OUTCOME OF OBSTETRIC VERSUS NON- OBSTETRIC ACUTE KIDNEY INJURY IN A TERTIARY CARE CENTRE
by: beauty suman, et al.
Published: (2025-02-01)

WCN25-287 CORRELATION OF VASCULAR CALCIFICATION WITH QUALITY OF LIFE AND FRAILTY IN CHRONIC KIDNEY DISEASE STAGE 4 AND 5 NON-DIALYSIS PATIENTS
by: Tanvi Thakker, et al.
Published: (2025-02-01)

WCN25-4048 A Randomized Controlled Study to Assess Catheter Salvageability by Ethanol Locking with Intravenous Antibiotics Versus Intravenous Antibiotics Alone in Tunneled Catheter-Related Bloodstream Infection
by: MK Hari Prasad, et al.
Published: (2025-02-01)

Outcomes of obstetric versus non-obstetric acute kidney injury: insights from an Indian tertiary care centre
by: Beauty Suman, et al.
Published: (2025-02-01)

WCN25-456 OUTCOME OF ARTERIO-VENOUS FISTULA MATURATION IN ELDERLY CHRONIC KIDNEY DISEASE PATIENTS
by: Abhishek Jha, et al.
Published: (2025-02-01)

WCN24-1384 COMPARISON BETWEEN METHODS TO EVALUATE SARCOPENIA, SARCOPENIC OBESITY AND MALNUTRITION IN CHRONIC HEMODIALYSIS PATIENTS
by: María Clara Delucchi, et al.
Published: (2024-04-01)

WCN25-3834 IMPACT OF DIETARY INTERVENTION ON QUALITY OF LIFE OUTCOMES IN STAGE 3, 4, AND NON DIALYSIS 5 CKD PATIENTS
by: HIMANSU MAHAPATRA, et al.
Published: (2025-02-01)

Genetic Patterns Related with the Development and Progression of Sarcopenia and Sarcopenic Obesity: A Systematic Review
by: Andreea-Dalila Nedelcu, et al.
Published: (2025-05-01)

WCN25-3821 Use of 24 hours Urine Urea Nitrogen (UUN) and Urinary Sodium with Protein and salt consumption in three different dietary protein intake groups of Chronic Kidney Disease patients
by: HIMANSU MAHAPATRA, et al.
Published: (2025-02-01)

Sarcopenic obesity is linked to worse clinical outcomes than sarcopenia or obesity alone in hospitalized older adults
by: Kamile Silay, et al.
Published: (2025-07-01)

Is Oral Function Associated with the Development of Sarcopenic Obesity and Sarcopenia in Older Adults? A Prospective Cohort Study
by: Sho Shirotori, et al.
Published: (2025-04-01)

Oral Postdialysis Cholecalciferol Supplementation in Patients on Maintenance Hemodialysis: A Dose-Response Approach
by: Eric Descombes, et al.
Published: (2014-01-01)

WCN25-1817 THE UNUSAL CASE SERIES OF PLA2R MEMBRANOUS NEPHROPATHY WITH PLA2R ANTIGEN ABSENT AND SERUM PLA2R ANTIBODY PRESENT
by: Anupam Agarwal, et al.
Published: (2025-02-01)

The role of cholecalciferol deficiency in the development of dermatoses in geriatric patients
by: Anna V. Urakova, et al.
Published: (2025-01-01)

Association of possible Sarcopenia, Sarcopenia and sarcopenic obesity with multimorbidity among middle-aged and older adults: findings from the China health and retirement longitudinal study
by: Kaixin Zhang, et al.
Published: (2025-03-01)

Probable and confirmed sarcopenia are still better predictors of disability than sarcopenic obesity following ESPEN/EASO consensus steps
by: Sibel Cavdar, et al.
Published: (2025-04-01)

Hand Grip Strength Cut‐Off Points as a Discriminator of Sarcopenia and Sarcopenic Obesity: Results from the ELSA‐Brasil Cohort
by: Clarice Alves Santos, et al.
Published: (2025-02-01)

Cholecalciferol (vitamin D3): efficacy, safety, and implications in public health
by: Esteban Ortiz-Prado, et al.
Published: (2025-06-01)

INVESTIGATING THE ANTI-INFLAMMATORY PROPERTIES OF CHOLECALCIFEROL IN RATS WITH CARRAGEENAN-INDUCED INFLAMMATION
by: Nina Doncheva, et al.
Published: (2022-02-01)

The relationship of cholecalciferol and parathyroid hormone with metabolic disorders in patients with arterial hypertension
by: M.M. Semіaniv, et al.
Published: (2024-06-01)

Liposomal encapsulation of cholecalciferol mitigates in vivo toxicity and delays tumor growth
by: Miriam Ezcurra-Hualde, et al.
Published: (2025-01-01)

Maternal and neonatal 25-OH cholecalciferol (25-OH-CC) levels
by: Şinasi Özsoylu
Published: (2014-06-01)

Prevalence and coexistence of malnutrition, sarcopenia, frailty and sarcopenic obesity among older adults in the community: Results from a prospective cohort study
by: Zhishan Jiang, et al.
Published: (2025-08-01)

Analysis of body composition, functionality and muscle-specific strength of older women with obesity, sarcopenia and sarcopenic obesity: a cross-sectional study
by: Leonardo Augusto da Costa Teixeira, et al.
Published: (2024-10-01)

HPLC-UV Method Development and Validation for Vitamin D<sub>3</sub> (Cholecalciferol) Quantitation in Drugs and Dietary Supplements
by: I. E. Shohin, et al.
Published: (2021-05-01)

Effect of cholecalciferol on immune and vascular function in non-diabetic chronic kidney disease
by: Kajal Kamboj, et al.
Published: (2025-04-01)

Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS)
by: Roger A. Fielding, et al.
Published: (2025-08-01)

Erratum: "HPLC-UV Method Development and Validation for Vitamin D<sub>3</sub> (Cholecalciferol) Quantitationin Drugs and Dietary Supplements"
by: I. E. Shohin, et al.
Published: (2021-11-01)

Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients: A Randomized Clinical Trial Study
by: Fiblia Fiblia, et al.
Published: (2022-09-01)

Sarcopenic Obesity and Endocrinal Adaptation with Age
by: Kunihiro Sakuma, et al.
Published: (2013-01-01)

Elevated 24,25-Dihydroxyvitamin D Serum Concentrations in Two Dogs with Cholecalciferol Toxicosis
by: Elizabeth Ippolito, et al.
Published: (2024-12-01)

Effects of Vitamin D Supplementation on Serum 25-Hydroxy Cholecalciferol in Inflammatory Bowel Diseases: A Meta-Analysis of Randomized Clinical Trials
by: Reza Ramezani, et al.
Published: (2024-11-01)

Bridging the Gap: Supplements Strategies from Experimental Research to Clinical Applications in Sarcopenic Obesity
by: Bogdana Virgolici, et al.
Published: (2024-11-01)

Evaluation of the effectiveness of vitamin D3 (cholecalciferol) in the correction of cognitive disorders in patients with cerebrovascular disease
by: G. I. Shvartsman, et al.
Published: (2021-06-01)

Effect of Reablement Strategies targeting Sarcopenia (ReStart-S) on sarcopenic older adults residing in long term care settings: A protocol for cluster randomized trial
by: Prabal Kumar, et al.
Published: (2025-02-01)

Sarcopenic obesity: epidemiology, pathogenesis and diagnostic criteria
by: S. A. Berns, et al.
Published: (2023-07-01)